MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s) (NCT02673021) | Clinical Trial Compass
TerminatedNot Applicable
MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
Stopped: Funding suspended prior to completing enrollment of all participants.
United States9 participantsStarted 2016-06-08
Plain-language summary
Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Subject must be at least 18 years old.
* Subject is able to understand the study procedures and provide informed consent.
* Subject is willing and able to complete the entire study as specified in the protocol, including the follow-up visits.
* Subject has lung lesion that is biopsy-proven cancer (of any type) or suspicious, with confirmation at the time of the procedure.
* Lung lesion(s) are reachable/treatable per clinician opinion.
* Subject can have other location of disease if it is controlled, or there are plans for control.
* Subject has 1 or more lung nodules (not more than 10), that have a mean diameter \<3 cm on axial CT scan.
* Life expectancy ≥6 months
Exclusion Criteria:
* Subject is pregnant or breast feeding.
* Subject has a significant clinical disease or condition, e.g. cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematological, psychiatric or neurologic that would preclude enrollment, as determined by the primary investigator.
* Subject has another location of disease that is not controlled, and there are no plans for control.
* Subject has more than 10 lung nodules.
What they're measuring
1
Efficacy of microwave ablation.
Timeframe: 3 months
2
Assessment of patient adverse events as defined by CTCAE.